Flash glucose monitoring system: impact on glycemic control and body mass index in type 1 diabetes mellitus
| العنوان: | Flash glucose monitoring system: impact on glycemic control and body mass index in type 1 diabetes mellitus |
|---|---|
| المؤلفون: | Juliana Marques Sá, Sara Lopes, Inês Ferreira Barros, Maria Joana Santos, Mariana Barbosa |
| المصدر: | Archives of Endocrinology and Metabolism, Vol 65, Iss 5, Pp 640-647 (2021) Archives of Endocrinology and Metabolism, Issue: ahead, Published: 25 OCT 2021 Archives of Endocrinology and Metabolism v.65 n.5 2021 Arquivos de Endocrinologia e Metabolismo Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM Archives of Endocrinology and Metabolism, Volume: 65, Issue: 5, Pages: 640-647, Published: 29 SEP 2021 |
| بيانات النشر: | Brazilian Society of Endocrinology and Metabolism, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Blood Glucose, medicine.medical_specialty, type 1 diabetes, Endocrinology, Diabetes and Metabolism, flash glucose monitoring, body mass index, Glycemic Control, Overweight, Diseases of the endocrine glands. Clinical endocrinology, chemistry.chemical_compound, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, Retrospective Studies, Glycemic, Type 1 diabetes, business.industry, Blood Glucose Self-Monitoring, Diabetes, nutritional and metabolic diseases, medicine.disease, RC648-665, Obesity, Diabetes Mellitus, Type 1, chemistry, Medicine, Glycated hemoglobin, medicine.symptom, business, Body mass index, Weight gain, glycated hemoglobin |
| الوصف: | Objective: Flash glucose monitoring (FGM) is increasingly used in type 1 diabetes mellitus (T1D) management. This study aimed to assess glycated hemoglobin (HbA1c) and body mass index (BMI) in the first year of FGM use in patients with T1D and to identify predictive factors of benefit associated with its use. Subjects and methods: Retrospective study of T1D patients, using FGM for ≥ 6 months and under intensive insulin therapy with multiple daily injections. Results: In 179 patients with a median (Md) age of 43.0 years (P25 31.0; P75 52.0) and disease duration of 18.0 years (P25 10.0; P75 28.0), initial HbA1c was 7.9% (P25 7.2; P75 8.8) and initial BMI was 24.0 kg/m2 (P25 21.9; P75 26.2). With FGM, HbA1c improved significantly to 7.6% (P25 7.0; P75 8.3) at 6 months and 7.7% (P25 6.95; P75 8.5) at 12 months (p < 0.05), with more patients with HbA1c < 7% (16.1% vs 22.5%) and fewer patients with HbA1c ≥ 8% (49.1% vs 35.8%) (p < 0.05). Initial HbA1c 8.0-8.9% (HR 1.886; 95% CI 1.321-2.450) and ≥ 9.0% (HR 3.108, 95% CI 2.454-3.761) predicted greater HbA1c reduction. BMI increased significantly, especially between 6 and 12 months (BMI Md 23.8 [P25 21.9; P75 26.2] kg/m2 and 24.0 [P25 22.0; P75 26.2] kg/m2, respectively) (p < 0.05). Overweight (HR 4.319, 95% CI 3.185-5.453) and obesity (HR 8.112, 95% CI 3.919-12.306) predicted greater weight gain. Conclusions: FGM use was associated with significant improvement in HbA1c, mainly in patients with worse previous glycemic control. It was also associated with increased BMI, especially if baseline BMI ≥ 25 kg/m2, so weight control strategies should be emphasized. |
| وصف الملف: | text/html |
| اللغة: | English |
| تدمد: | 2359-4292 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02d19a010121c80a7df4798492672feeTest http://www.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972021000500640&tlng=enTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....02d19a010121c80a7df4798492672fee |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23594292 |
|---|